Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/215680
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding |
Autor: | Albiñana, Virginia CSIC; Cuesta, Ángel M. CSIC ORCID ; Rojas-P, Isabel de CSIC; Gallardo-Vara, Eunate CSIC ORCID; Recio-Poveda, Lucía ; Bernabéu, Carmelo CSIC ORCID ; Botella, Luisa María CSIC ORCID | Palabras clave: | HHT ALK1 Endoglin Raloxifene Bazedoxifene Tranexamic acid Propranolol FK506 Etamsylate N-acetylcysteine |
Fecha de publicación: | 2020 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Journal of Clinical Medicine 9(6): 1766 (2020) | Resumen: | The diagnosis of hereditary hemorrhagic telangiectasia (HHT) is based on the Curaçao criteria: epistaxis, telangiectases, arteriovenous malformations in internal organs, and family history. Genetically speaking, more than 90% of HHT patients show mutations in ENG or ACVRL1/ALK1 genes, both belonging to the TGF-β/BMP9 signaling pathway. Despite clear knowledge of the symptoms and genes of the disease, we still lack a definite cure for HHT, having just palliative measures and pharmacological trials. Among the former, two strategies are: intervention at “ground zero” to minimize by iron and blood transfusions in order to counteract anemia. Among the later, along the last 15 years, three different strategies have been tested: (1) To favor coagulation with antifibrinolytic agents (tranexamic acid); (2) to increase transcription of ENG and ALK1 with specific estrogen-receptor modulators (bazedoxifene or raloxifene), antioxidants (N-acetylcysteine, resveratrol), or immunosuppressants (tacrolimus); and (3) to impair the abnormal angiogenic process with antibodies (bevacizumab) or blocking drugs like etamsylate, and propranolol. This manuscript reviews the main strategies and sums up the clinical trials developed with drugs alleviating HHT. | Descripción: | © 2020 by the authors. | Versión del editor: | https://doi.org/10.3390/jcm9061766 | URI: | http://hdl.handle.net/10261/215680 | DOI: | 10.3390/jcm9061766 | E-ISSN: | 2077-0383 |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Review_Albiñana_Art2020.pdf | 1,69 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
12
checked on 20-mar-2024
SCOPUSTM
Citations
18
checked on 28-mar-2024
WEB OF SCIENCETM
Citations
19
checked on 27-feb-2024
Page view(s)
126
checked on 29-mar-2024
Download(s)
154
checked on 29-mar-2024